Stock Update: Eli Lilly & Company (NYSE:LLY) – Elanco, EnBiotix Establish Collaboration Exploring Engineered Phage Technology

[Business Wire] – Today Elanco Animal Health, a division of Eli Lilly and Company, and EnBiotix, Inc., announced a collaboration to explore the application of EnBiotix’s engineered phage technology in specific animal health targets. Read more on this. Eli Lilly and Company (LLY) , valued at $77.81B, opened at $73.47. Looking at the stock, its one day range is $72.97 to $73.89 with the price of the stock fluctuating between $67.88 to $92.85 over the last 52 weeks. LLY shares are currently priced at 20.65x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -0.02x earnings multiple for the same period. The company pays shareholders $2.04 per share in dividend income per year, for a current yield of 2.76%. Consensus earnings for the current quarter by the 17 sell-side analysts covering the stock is an estimate of $0.85 per share, which would be $0.05 worse than the year-ago quarter and a $0.02 sequential decrease. The full-year EPS estimate is $3.57, which would be a $0.14 better than last year. The quarterly earnings estimate is predicated on a consensus revenue forecast of $5.14 Billion. If reported, that would be a 3.21% increase over the year-ago quarter. More recently, Societe Generale Initiated LLY at Hold (Apr 6, 2016). Previously, BMO Capital Markets upgraded LLY from Market Perform to Outperform. The average price target for LLY shares by the analysts covering it is $95.71, which is 30.27% above where the stock opened. See more in (NYSE:LLY) Similar Articles: Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly’s Taltz® (ixekizumab) Now Available in the U.S. for the Treatment of Moderate-to-Severe Plaque Psoriasis Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly To Present At Leerink Partners Global Healthcare Conference Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly and Incyte Announce Submission of New Drug Application to FDA for Oral Once-Daily Baricitinib for Treatment of Moderate-to-Severe Rheumatoid Arthritis